These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
311 related articles for article (PubMed ID: 15297048)
1. A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine. Ault KA; Giuliano AR; Edwards RP; Tamms G; Kim LL; Smith JF; Jansen KU; Allende M; Taddeo FJ; Skulsky D; Barr E Vaccine; 2004 Aug; 22(23-24):3004-7. PubMed ID: 15297048 [TBL] [Abstract][Full Text] [Related]
2. Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Villa LL; Ault KA; Giuliano AR; Costa RL; Petta CA; Andrade RP; Brown DR; Ferenczy A; Harper DM; Koutsky LA; Kurman RJ; Lehtinen M; Malm C; Olsson SE; Ronnett BM; Skjeldestad FE; Steinwall M; Stoler MH; Wheeler CM; Taddeo FJ; Yu J; Lupinacci L; Railkar R; Marchese R; Esser MT; Bryan J; Jansen KU; Sings HL; Tamms GM; Saah AJ; Barr E Vaccine; 2006 Jul; 24(27-28):5571-83. PubMed ID: 16753240 [TBL] [Abstract][Full Text] [Related]
3. Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine. Brown DR; Fife KH; Wheeler CM; Koutsky LA; Lupinacci LM; Railkar R; Suhr G; Barr E; Dicello A; Li W; Smith JF; Tadesse A; Jansen KU Vaccine; 2004 Jul; 22(21-22):2936-42. PubMed ID: 15246630 [TBL] [Abstract][Full Text] [Related]
5. Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. Pinto LA; Edwards J; Castle PE; Harro CD; Lowy DR; Schiller JT; Wallace D; Kopp W; Adelsberger JW; Baseler MW; Berzofsky JA; Hildesheim A J Infect Dis; 2003 Jul; 188(2):327-38. PubMed ID: 12854090 [TBL] [Abstract][Full Text] [Related]
6. Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy women. Fife KH; Wheeler CM; Koutsky LA; Barr E; Brown DR; Schiff MA; Kiviat NB; Jansen KU; Barber H; Smith JF; Tadesse A; Giacoletti K; Smith PR; Suhr G; Johnson DA Vaccine; 2004 Jul; 22(21-22):2943-52. PubMed ID: 15246631 [TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and reactogenicity of a novel vaccine for human papillomavirus 16: a 2-year randomized controlled clinical trial. Poland GA; Jacobson RM; Koutsky LA; Tamms GM; Railkar R; Smith JF; Bryan JT; Cavanaugh PF; Jansen KU; Barr E Mayo Clin Proc; 2005 May; 80(5):601-10. PubMed ID: 15887427 [TBL] [Abstract][Full Text] [Related]
8. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Olsson SE; Villa LL; Costa RL; Petta CA; Andrade RP; Malm C; Iversen OE; Høye J; Steinwall M; Riis-Johannessen G; Andersson-Ellstrom A; Elfgren K; von Krogh G; Lehtinen M; Paavonen J; Tamms GM; Giacoletti K; Lupinacci L; Esser MT; Vuocolo SC; Saah AJ; Barr E Vaccine; 2007 Jun; 25(26):4931-9. PubMed ID: 17499406 [TBL] [Abstract][Full Text] [Related]
9. Neutralization of human papillomavirus type 11 (HPV-11) by serum from women vaccinated with yeast-derived HPV-11 L1 virus-like particles: correlation with competitive radioimmunoassay titer. Brown DR; Bryan JT; Schroeder JM; Robinson TS; Fife KH; Wheeler CM; Barr E; Smith PR; Chiacchierini L; DiCello A; Jansen KU J Infect Dis; 2001 Nov; 184(9):1183-6. PubMed ID: 11598842 [TBL] [Abstract][Full Text] [Related]
10. Review of current knowledge on HPV vaccination: an appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening. Arbyn M; Dillner J J Clin Virol; 2007 Mar; 38(3):189-97. PubMed ID: 17258503 [TBL] [Abstract][Full Text] [Related]
11. Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species. Gambhira R; Gravitt PE; Bossis I; Stern PL; Viscidi RP; Roden RB Cancer Res; 2006 Dec; 66(23):11120-4. PubMed ID: 17145854 [TBL] [Abstract][Full Text] [Related]
12. Vaccines for the prevention of human papillomavirus and associated gynecologic diseases: a review. Ault KA Obstet Gynecol Surv; 2006 Jun; 61(6 Suppl 1):S26-31. PubMed ID: 16729901 [TBL] [Abstract][Full Text] [Related]
13. Immune responses induced by lower airway mucosal immunisation with a human papillomavirus type 16 virus-like particle vaccine. Nardelli-Haefliger D; Lurati F; Wirthner D; Spertini F; Schiller JT; Lowy DR; Ponci F; De Grandi P Vaccine; 2005 May; 23(28):3634-41. PubMed ID: 15882523 [TBL] [Abstract][Full Text] [Related]
14. Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Pastrana DV; Buck CB; Pang YY; Thompson CD; Castle PE; FitzGerald PC; Krüger Kjaer S; Lowy DR; Schiller JT Virology; 2004 Apr; 321(2):205-16. PubMed ID: 15051381 [TBL] [Abstract][Full Text] [Related]
15. Prophylactic HPV vaccines: reducing the burden of HPV-related diseases. Villa LL Vaccine; 2006 Mar; 24 Suppl 1():S23-8. PubMed ID: 16194583 [TBL] [Abstract][Full Text] [Related]
16. Immunobiology of human papillomavirus infection and vaccination - implications for second generation vaccines. Stanley M; Gissmann L; Nardelli-Haefliger D Vaccine; 2008 Aug; 26 Suppl 10():K62-7. PubMed ID: 18847558 [TBL] [Abstract][Full Text] [Related]
17. Human papillomavirus vaccines. Stanley MA Rev Med Virol; 2006; 16(3):139-49. PubMed ID: 16710836 [TBL] [Abstract][Full Text] [Related]
18. [Cervical cancer prevention: the impact of HPV vaccination]. Monsonégo J Gynecol Obstet Fertil; 2006 Mar; 34(3):189-201. PubMed ID: 16529969 [TBL] [Abstract][Full Text] [Related]
19. Strategies for the prevention of cervical cancer by human papillomavirus vaccination. Williamson AL; Passmore JA; Rybicki EP Best Pract Res Clin Obstet Gynaecol; 2005 Aug; 19(4):531-44. PubMed ID: 16150392 [TBL] [Abstract][Full Text] [Related]